{"nctId":"NCT00550238","briefTitle":"A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis","startDateStruct":{"date":"2007-07"},"conditions":["Parkinson's Disease Psychosis"],"count":459,"armGroups":[{"label":"Pimavanserin tartrate (ACP-103)","type":"EXPERIMENTAL","interventionNames":["Drug: Pimavanserin tartrate (ACP-103)"]}],"interventions":[{"name":"Pimavanserin tartrate (ACP-103)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject has completed the treatment period of a previous blinded study of pimavanserin\n* The subject is willing and able to provide consent\n* Caregiver is willing and able to accompany the subject to all visits\n\nExclusion Criteria:\n\n* Subject has current evidence of a serious and or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic or other medical disorder\n* Subject is judged by the Investigator to be inappropriate for the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Safety: Number (%) of Patients With Drug-related Treatment-emergent Adverse Events (AEs)","description":"Number (%) of patients with drug-related treatment-emergent AEs (i.e. AEs reported by the Investigator as possibly, probably, or highly probably related to study drug)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"180","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":188,"n":459},"commonTop":["Fall","Urinary tract infection","Hallucination","Weight decreased","Confusional state"]}}}